Location, location

Following the publication of full data from the first successful Phase II trial of a gene therapy candidate for Parkinson's disease, Neurologix Inc. believes it will be able to replace deep brain stimulation as the standard of care for advanced PD. The company says the reason NLX-P101 succeeded is the location within the brain where the therapy is infused.

In its initial readout last June, Neurologix reported NLX-P101 (AAV-GAD) met the primary endpoint of significantly improving off-medication motor scores from baseline to six months vs. a sham infusion of saline. Updated results published in The Lancet last week revealed the mean improvement was 23.1% (8 points) for NLX-P101 (AAV-GAD) vs. 12.7% (4.7 points) for sham control (p=0.04)...